

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

NCT06431776

Status	RECRUITING
Phase	Phase 3
Sponsor	Savara Inc.
Enrollment	5 participants

Key Eligibility Criteria

Inclusion (4)

- Be e6 and \<18 years of age, at the time of signing the informed consent and informed assent (if applicable).
- Have a history of pulmonary alveolar proteinosis, based on examination of a lung biopsy, bronchoalveolar lavage cytology, or a high-resolution computed tomogram of the chest.
- Have a positive serum anti-GM-CSF autoantibody test result confirming aPAP.
- Have a hemoglobin (Hb)-adjusted diffusing capacity of the lung for carbon monoxide (DLCO) d70% predicted at Screening.

Exclusion (2)

- Have a diagnosis of hereditary (congenital) or secondary PAP, or a metabolic disorder of surfactant production.
- Have undergone treatment with Lung Lavage (WLL) within 1 month of Baseline

Locations (1 total)

Ludwig Maximilians Universität München - Dr. von Haunersches Kinderspital - Kinderklinik und Kinderpoliklinik, München, Germany